SCHEMBL4635795

SCHEMBL4635795

Clc1ccc(COC2CN(C(c3ccccc3)c3ccccc3)C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.49
KCNH2 Q12809 4/20 0.46
CHRM2 P08172 3/20 0.46
ADRA2A P08913 3/20 0.46
ADRA1A P35348 3/20 0.46
DRD3 P35462 3/20 0.46
HTR1A P08908 2/20 0.46
CHRM1 P11229 2/20 0.46
DRD1 P21728 2/20 0.46
TBXA2R P21731 2/20 0.46
SLC6A2 P23975 2/20 0.46
SLC6A4 P31645 2/20 0.46
SLC6A3 Q01959 2/20 0.46
CTSL P07711 1/20 0.46
CTSB P07858 1/20 0.46
CTSK P43235 1/20 0.46
BCL2 P10415 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
NAAA Q02083 2/20 0.45
CYP2D6 P10635 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1768861 0.90 CTSL (0.55) TACR1CTSLCTSBCTSKHRH3
SCHEMBL4635725 0.86 NAAA (0.50) TACR1CTSLCTSBCTSKNAAA
SCHEMBL4636063 0.85 TACR1 (0.48) TACR1KCNH2CTSLCTSBCTSK
SCHEMBL4636695 0.82 NAAA (0.53) TACR1CTSLCTSBCTSKNAAA
SCHEMBL11234409 0.79 CARM1 (0.48) TACR1SLC6A4CTSLCTSBCTSK
SCHEMBL6584924 0.78 CHRM2 (0.49) KCNH2CHRM2ADRA2AADRA1ADRD3
SCHEMBL1769180 0.78 CHRM2 (0.35) TACR1KCNH2CHRM2ADRA2AADRA1A
SCHEMBL4077695 0.77 MEN1 (0.58) KCNH2CHRM2ADRA2AADRA1ADRD3
SCHEMBL2007270 0.75 OPRM1 (0.47) KCNH2CHRM2ADRA2ADRD3CHRM1
SCHEMBL4182462 0.75 OPRM1 (0.46) KCNH2CHRM2ADRA2AADRA1ADRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11214578-B2 Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof NORTHEASTERN UNIVERSITY (US) 2022-01-04 US disclosed
US-20200148696-A1 Urea/Carbamates FAAH MAGL Or Dual FAAH/MAGL Inhibitors And Uses Thereof NORTHEASTERN UNIVERSITY 2020-05-14 US disclosed
US-10570146-B2 Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof NORTHEASTERN UNIVERSITY (US) 2020-02-25 US disclosed
US-20170247387-A1 UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF NORTHEASTERN UNIVERSITY 2017-08-31 US disclosed
US-20170247387-A1 UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF NORTHEASTERN UNIVERSITY 2017-08-31 US disclosed
WO-2016014975-A2 UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF NORTHEASTERN UNIVERSITY (US) 2016-01-28 WO disclosed
WO-2016014975-A2 UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF NORTHEASTERN UNIVERSITY (US) 2016-01-28 WO disclosed
EP-1617839-B1 THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY VERNALIS RES LTD (GB) 2008-06-18 EP disclosed
US-20060276452-A1 Use of azetidinecarboxamide derivatives in therapy VERNALIS RESEARCH LIMITED (GB) 2006-12-07 US disclosed
EP-1617839-A1 THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY VERNALIS RESEARCH LIMITED (GB) 2006-01-25 EP disclosed
WO-2004096209-A1 THE USE OF AZETIDINECARBOXAMIDE DERIVATIVES IN THERAPY VERNALIS RESEARCH LIMITED (GB) 2004-11-11 WO disclosed
EP-1049672-B1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RES LTD (GB) 2003-09-17 EP disclosed
EP-1212054-A2 AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES VERNALIS RESEARCH LIMITED (GB) 2002-06-12 EP disclosed
US-6403574-B1 TRANQUILIZERS, ANTIEPILEPTIC, MUSCLE RELAXATION PRIOR TO SURGERY VERNALIS RESEARCH LIMITED (GB) 2002-06-11 US disclosed
WO-2001007023-A2 AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES VERNALIS RESEARCH LIMITED (GB) 2001-02-01 WO disclosed
EP-1049672-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 2000-11-08 EP disclosed
WO-1999037612-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 1999-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11214578-B2 Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof FAAH, FAAH2, MGLL TACR1 1670/4885KCNH2 1929/4885CHRM2 2057/4885
US-10570146-B2 Urea/carbamates FAAH MAGL or dual FAAH/MAGL inhibitors and uses thereof FAAH, FAAH2, MGLL TACR1 1614/4885KCNH2 2080/4885CHRM2 1796/4885
US-20170247387-A1 UREA/CARBAMATES FAAH MAGL OR DUAL FAAH/MAGL INHIBITORS AND USES THEREOF FAAH, FAAH2, MGLL TACR1 2035/4885KCNH2 3068/4885CHRM2 2240/4885
US-20060276452-A1 Use of azetidinecarboxamide derivatives in therapy CNR1, CNR2, GPR18 TACR1 76/4885KCNH2 368/4885CHRM2 185/4885
US-20200148696-A1 Urea/Carbamates FAAH MAGL Or Dual FAAH/MAGL Inhibitors And Uses Thereof FAAH, MGLL, FAAH2 TACR1 2702/4885KCNH2 3539/4885CHRM2 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.